

2009 3rd Quarter Literature Review



AE-PCOS Quarterly Literature Summary & Review October 2009

Steven R. Lindheim, M.D, M.M.M., Editor

ADIPOSE TISSUE AND HORMONES

- 1. Adipose tissue expandability and the early origins of PCOS. de Zegher F, Lopez-Bermejo A, Ibáñez L. Trends Endocrinol Metab. 2009 Sep 29.**
- 2. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Senay A, Mithat B, Alpaslan T, Ebru K, Deniz G. Gynecol Endocrinol. 2009 Sep 15:1-6.**

2009 3rd Quarter Literature Review

3. Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, Lewandowski KC, O'Hare JP, Lehnert H, Randeve HS. Diabetes. 2009 Jun 5.
4. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Godoy-Matos AF, Vaisman F, Pedrosa AP, Farias ML, Mendonca LM, Pinheiro MF. Gynecol Endocrinol. 2009 Jun 12:1-6.
5. Reduced serum ghrelin in a putative postmenopausal polycystic ovary syndrome phenotype. Krentz AJ, Barrett-Connor E. Fertil Steril. 2009 Jun 17.
6. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. Svendsen PF, Madsbad S, Nilas L, Paulsen SK, Pedersen SB. Int J Obes (Lond). 2009 Aug 25.
7. The FTO gene modifies weight, fat mass and insulin sensitivity in women with polycystic ovary syndrome, where its role may be larger than in other phenotypes. Kowalska I, Malecki MT, Strackowski M, Skupien J, Karczewska-Kupczewska M, Nikolajuk A, Szopa M, Adamska A, Wawrusiewicz-Kurylonek N, Wołczynski S, Sieradzki J, Gorska M. Diabetes Metab. 2009 Jul 20.

ADOLESCENCE

2009 3rd Quarter Literature Review

8. Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents. **Ropelato MG, García Rudaz MC, Escobar ME, Bengolea SV, Calcagno ML, Veldhuis JD, Barontini M.** J Clin Endocrinol Metab. 2009 Jun 30.
9. Hypothalamic amenorrhea in young women with underlying polycystic ovary syndrome. **Sum M, Warren MP.** Fertil Steril. 2009 Jul 7.
10. A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents. **de Sousa G, Schlüter B, Buschatz D, Menke T, Trowitzsch E, Andler W, Reinehr T.** Sleep Breath. 2009 Jul 8.
11. Glucose Metabolism in Overweight Hispanic Adolescents With and Without Polycystic Ovary Syndrome. **Nur MM, Newman IM, Siqueira LM.** Pediatrics. 2009 Aug 24.
12. Characteristics of Adolescents Presenting to a Multidisciplinary Clinic for Polycystic Ovarian Syndrome. **Tracy Bekx M, Connor EC, Allen DB.** J Pediatr Adolesc Gynecol. 2009 Jul 31.
13. Early polycystic ovary syndrome as a possible etiology of unexplained premenarcheal ovarian torsion. **Shah AA, Likes CE, Price TM.** J Pediatr Adolesc Gynecol. 2009 Aug; 22(4): 265-9.
14. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. **Harris-Glocker M, Davidson K, Kochman L, Guzick D, Hoeger K.** Fertil Steril. 2009 Sep 23.

2009 3rd Quarter Literature Review

- 15. Endometrial Thickness, Uterine, and Ovarian Ultrasonographic Features in Adolescents with Polycystic Ovarian Syndrome. Shah B, Parnell L, Milla S, Kessler M, David R. J Pediatr Adolesc Gynecol. 2009 Sep 2.**
- 16. Adiponectin and resistin concentrations after glucose load in adolescents with polycystic ovary syndrome. Guven A, Ozgen T, Aliyazicioğlu Y. Gynecol Endocrinol. 2009 Jul 23:1-9.**

AMH

- 17. The value of measuring anti-Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Amer SA, Li TC, Ledger WL. Hum Reprod. 2009 Jul 29.**
- 18. Testosterone-induced downregulation of anti-Müllerian hormone expression in granulosa cells from small bovine follicles. Crisosto N, Sir-Petermann T, Greiner M, Maliqueo M, Moreno M, Aedo P, Lara HE. Endocrine. 2009 Oct; 36(2): 339-45.**

2009 3rd Quarter Literature Review

CANCER

19.Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome. Villavicencio A, Goyeneche A, Telleria C, Bacallao K, Gabler F, Fuentes A, Vega M. Gynecol Oncol. 2009 Jul 22.

20.Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Reprod Biomed Online. 2009 Sep; 19(3):398-405.

CARDIOVASCULAR RISK

21.Association of polycystic ovary syndrome with cardiovascular risk factors. Akram T, Hasan S, Imran M, Karim A, Arslan M. Gynecol Endocrinol. 2009 Jul 23:1-7.

22.Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Carmina E, Guastella E, Longo R, Rini G, Lobo RA. Eur J Endocrinol. 2009 Jul 15.

23.Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Battaglia C, Mancini F, Fabbri R, Persico N, Busacchi P, Facchinetti F, Venturoli S. Fertil Steril. 2009 Jul 8.

2009 3rd Quarter Literature Review

- 24.**Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome.
Ciccone MM, Favale S, Bhuvu A, Scicchitano P, Caragnano V, Lavopa C, De Pergola G, Loverro G. Vasc Health Risk Manag. 2009; 5(3):561-6.
- 25.**The relationship of the Fas 670 A/G gene polymorphism with cardiovascular risk factors in polycystic ovary syndrome (PCOS) patients. Cetinkalp S, Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Ozgen AG, Saygili F, Yilmaz C. Gynecol Endocrinol. 2009 Aug 26:1-6.
- 26.**Relationship between interleukin-6 levels and ambulatory blood pressure in women with polycystic ovary syndrome.
Kaya C, Pabuçcu R, Koca C, Oğuz AK, Erkan AF, Korkmaz A, Erbaş D. Fertil Steril. 2009 Sep 25.
- 27.**High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF. Arch Gynecol Obstet. 2009 Sep 22.
- 28.**Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome.
Rocha MP, Maranhão RC, Seydell TM, Barcellos CR, Baracat EC, Hayashida SA, Bydlowski SP, Marcondes JA. Fertil Steril. 2009 Sep 16.
- 29.**Optimal Waist Circumference for Prediction of Metabolic Syndrome in Young Korean Women With Polycystic Ovary Syndrome. Oh JY, Sung YA, Lee HJ, Oh JY, Chung HW, Park H. Obesity (Silver Spring). 2009 Sep 17.

2009 3rd Quarter Literature Review

30. The relationship of the interleukin-6 -174 G>C gene polymorphism with cardiovascular risk factors in Turkish polycystic ovary syndrome patients. Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Yilmaz C. Int J Immunogenet. 2009 Oct; 36(5):283-8.
31. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Bilgir O, Kebapcilar L, Taner C, Bilgir F, Kebapcilar A, Bozkaya G, Yildiz Y, Yuksel A, Sari I. Intern Med. 2009;48(14):1193-9.
32. Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. Fan P, Liu HW, Wan DH, Li Y, Song Q, Bai H. Fertil Steril. 2009 Jul 9.

FERTILITY

33. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. Sun L, Lv H, Wei W, Zhang D, Guan Y. J Endocrinol Invest. 2009 Jul 28.

2009 3rd Quarter Literature Review

34.L-Selectin ligands in human endometrium: comparison of fertile and infertile subjects. Margarit L, Gonzalez D, Lewis PD, Hopkins L, Davies C, Conlan RS, Joels L, White JO. Hum Reprod. 2009 Jul 22.

35.Obesity and female fertility: a primary care perspective. Wilkes S, Murdoch A.J Fam Plann Reprod Health Care. 2009 Jul; 35(3):181-5.

36.The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. Hum Reprod. 2009 Jul 18.

2009 3rd Quarter Literature Review

GENETICS

37. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. San-Millán JL, Escobar-Morreale HF. Clin Endocrinol (Oxf). 2009 Aug 4.
38. The role of genes in the polycystic ovary syndrome: Predisposition and mechanisms. Deligeoroglou E, Kouskouti C, Christopoulos P. Gynecol Endocrinol. 2009 Jul 13:1-7.
39. Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome. Vural P, Küskü-Kiraz Z, Dođru-Abbasođlu S, Cil E, Karadađ B, Akgül C, Uysal M. Eur J Obstet Gynecol Reprod Biol. 2009 Jul 22.
40. Association between ACE gene I/D polymorphisms and hyperandrogenism in women with polycystic ovary syndrome (PCOS) and controls. Sun J, Fan H, Che Y, Cao Y, Wu X, Sun HX, Liang F, Yi L, Wang Y. BMC Med Genet. 2009 Jul 14;10:64.
41. Association study of AMP-activated protein kinase (AMPK) subunit genes in polycystic ovary syndrome. Sproul K, Jones M, Azziz R, Goodarzi M. Eur J Endocrinol 2009; 161: 405-9

2009 3rd Quarter Literature Review

42. Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Prodoehl MJ, Hatzirodos N, Irving-Rodgers HF, Zhao ZZ, Painter JN, Hickey TE, Gibson MA, Rainey WE, Carr BR, Mason HD, Norman RJ, Montgomery GW, Rodgers RJ. Mol Hum Reprod. 2009 Aug 19.
43. Family-Based Association Study of the MCF2L2 Gene and Polycystic Ovary Syndrome. Zheng Q, Shi Y, Yang Z, Xu X, Wang L, Xue F, Gu HF, Chen ZJ. Gynecol Obstet Invest. 2009 Jul 31; 68(3):171-173.
44. Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome. Vural P, Küskü-Kiraz Z, Doğru-Abbasoğlu S, Cil E, Karadağ B, Akgül C, Uysal M. Eur J Obstet Gynecol Reprod Biol. 2009 Jul 22.
45. Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with polycystic ovary syndrome in Chinese women. Liu X, Li L, Chen ZJ, Lu Z, Shi Y, Zhao Y. Gynecol Endocrinol. 2009 Aug 28:1-6.
46. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Kawai T, Ng MC, Hayes MG, Yoshiuchi I, Tsuchiya T, Robertson H, Cox NJ, Polonsky KS, Bell GI, Ehrmann DA. Diabetes Res Clin Pract. 2009 Sep 24.
47. The role of family history in clinical symptoms and therapeutic outcomes of women with polycystic ovary syndrome. Hu Z, Wang Y, Qiao J, Li M, Chi

2009 3rd Quarter Literature Review

48.Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data. **Mohamed-Hussein ZA, Harun S.** Theor Biol Med Model. 2009 Sep 1;6:18.

HIRSUTISM-ANDROGEN EXCESS

49.Hirsutism. **Shah D, Patel S.** Gynecol Endocrinol. 2009 Mar; 25(3):140-8.

50.Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. **Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A.** Gynecol Endocrinol. 2009 Jun 23:1-6.

51.Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. **Kebapcilar L, Bilgir O, Taner CE, Kebapcilar AG, Kozaci DL, Alacacioglu A, Yildiz Y, Yuksel A, Sari I.** Arch Gynecol Obstet. 2009 Aug 5.

52.Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. a randomized controlled trial. **Grant P.** Phytother Res. 2009 Jul 7.

2009 3rd Quarter Literature Review

INFLAMMATION

53. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Tosi F, Dorizzi R, Castello R, Maffei C, Spiazzi G, Zoppini G, Muggeo M, Moghetti P. Eur J Endocrinol. 2009 Aug 27.
54. The relationship between follistatin and chronic low-grade inflammation in women with polycystic ovary syndrome. Chen MJ, Chen HF, Chen SU, Ho HN, Yang YS, Yang WS. Fertil Steril. 2009 Jul 8.
55. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Samy N, Hashim M, Sayed M, Said M. Dis Markers. 2009; 26(4):163-70.

INSULIN RESISTANCE-GLUCOSE TOLERANCE

56. Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant states. Woods YL, Petrie JR, Sutherland C. Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):187-98.
57. Serum insulin patterns and the relationship between insulin sensitivity and glycaemic profile in women with polycystic ovary syndrome. Seneviratne HR, Lankeshwara D, Wijeratne S, Somasunderam N, Athukorale D. BJOG. 2009 Sep 23.
58. Impaired Glucose Metabolism in Women with Polycystic Ovary Syndrome. Vrbikova J, Fanta M, Cibula D, Vondra K, Bendlova B. Gynecol Obstet Invest. 2009 Aug 7;68(3):186-190
59. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Lee H, Oh JY, Sung YA, Chung H, Cho WY. Endocrine. 2009 Aug 14.
60. Beta cell function and insulin sensitivity in women with polycystic ovary syndrome: Influence of the family history of type 2 diabetes mellitus. Vrbikova J, Bendlova B, Vankova M, Dvorakova K, Grimmichova T, Vondra K, Pacini G. Gynecol Endocrinol. 2009 Jul 1:1-6.

2009 3rd Quarter Literature Review

LIVER

61. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Do androgens play a role? Kauffman RP, Baker TE, Baker V, Kauffman MM, Daniel Castracane V. *Gynecol Endocrinol.* 2009 Aug 12:1-8.
62. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E. *Hormones (Athens).* 2009 Jul-Sep;8(3):199-206.
63. Omega-3 fatty acid supplementation decreases liver fat content in Polycystic Ovarian Syndrome: a randomised controlled trial employing proton magnetic resonance spectroscopy. Cussons AJ, Watts GF, Mori TA, Stuckey BG. *J Clin Endocrinol Metab.* 2009 Jul 21.

NEUROENDOCRINE REGULATION

64. Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome. Priyadarshani A. *J Endocrinol Invest.* 2009 Jul 17.

2009 3rd Quarter Literature Review

NUTRITION-DIET-EXERCISE

65. Exercise Training Improved Insulin Sensitivity and Ovarian Morphology in Rats with Polycystic Ovary Syndrome. Qiu S, Wu C, Lin F, Chen L, Huang Z, Jiang Z. Horm Metab Res. 2009 Aug 19.

66. The relation between athletic sports and prevalence of amenorrhea and oligomenorrhea in Iranian female athletes. Dadgostar H, Razi M, Aleyasin A, Alenabi T, Dahaghin S. Sports Med Arthrosc Rehabil Ther Technol. 2009 Jul 30;1(1):16.

67. Dietary management of women with polycystic ovary syndrome in the United Kingdom: the role of dietitians. Jeanes YM, Barr S, Smith K, Hart KH. J Hum Nutr Diet. 2009 Sep 4.

OVARY

68. Elevated levels of oxidised low-density lipoprotein and of catalase activity in follicular fluid of obese women. Bausenwein J, Serke H, Eberle K, Hirrlinger J, Jogschies P, Hmeidani FA, Blumenauer V, Spaniel-Borowski K. Mol Hum Reprod. 2009 Sep 3.

2009 3rd Quarter Literature Review

69. Role of Isoprenylation in Simvastatin-Induced Inhibition of Ovarian Theca-Interstitial Growth in the Rat. Rzepczynska IJ, Piotrowski PC, Wong DH, Cress AB, Villanueva J, Duleba AJ. Biol Reprod. 2009 Jul 1.
70. Lysyl oxidase interacts with AGEs signaling to modulate collagen synthesis in polycystic ovarian tissue. Papachroni KK, Piperi C, Levidou G, Korkolopoulou P, Pawelczyk L, Diamanti-Kandarakis E, Papavassiliou AG. J Cell Mol Med. 2009 Jul 6.

PCOS PHENOTYPES

71. Effect of body mass index on clinical manifestations in patients with polycystic ovary syndrome. Tamimi W, Siddiqui IA, Tamim H, Aleisa N, Adham M. Int J Gynaecol Obstet. 2009 Jul 2.
72. Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. Karkanaki A, Piouka A, Katsikis I, Farmakiotis D, Macut D, Panidis D. Fertil Steril. 2009 Aug 21.
73. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. BJOG. 2009 Sep 14.

2009 3rd Quarter Literature Review

- 74.The insulin-resistant phenotype of polycystic ovary syndrome. Svendsen PF, Madsbad S, Nilas L. Fertil Steril. 2009 Jul 4.
- 75.Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant. Wang Y, Qu J, Wu X, Hou L, Erkkola R, Wang Y. Fertil Steril. 2009 Sep 25.
- 76.Polycystic ovary syndrome, obesity and reproductive implications. Hirschberg AL. Womens Health (Lond Engl). 2009 Sep; 5(5):529-40

2009 3rd Quarter Literature Review

PREGNANCY

77. Does the presence of polycystic ovary syndrome increase the risk of obstetrical complications in women with gestational diabetes? [Alshammari A, Hanley A, Ni A, Tomlinson G, Feig DS.](#) J Matern Fetal Neonatal Med. 2009 Aug 27:1-5.

THYROID

78. Association of thyroid-stimulating hormone with insulin resistance and androgen parameters in women with PCOS. [Dittrich R, Kajaia N, Cupisti S, Hoffmann I, Beckmann MW, Mueller A.](#) Reprod Biomed Online. 2009 Sep; 19(3):319-25.

TREATMENT OF PCOS – GENERAL REVIEWS

79. Polycystic ovaries and infertility: Our experience. [Rajashekar L, Krishna D, Patil M.J](#) Hum Reprod Sci. 2008 Jul;1(2):65-72.

TREATMENT OF PCOS – CLOMIPHENE

2009 3rd Quarter Literature Review

80. Luteal-phase clomiphene citrate in PCOS. Gada D. Fertil Steril. 2009 Aug 21.

TREATMENT OF PCOS – METFORMIN AND INSULIN SENSITIZING DRUGS

81. **Targeting insulin sensitivity in the treatment of polycystic ovary syndrome. Pasquali R, Gambineri A. Expert Opin Ther Targets. 2009 Aug 4.**

82. **The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence. Leeman L, Acharya U. J Obstet Gynaecol. 2009 Aug;29(6):467-72.**

2009 3rd Quarter Literature Review

- 83.** Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Qublan HS, Al-Khaderei S, Abu-Salem AN, Al-Zpoon A, Al-Khateeb M, Al-Ibrahim N, Megdadi M, Al-Ahmad N. J Obstet Gynaecol. 2009 Oct;29(7):651-5.
- 84.** Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. Ashrafinia M, Hosseini R, Moini A, Eslami B, Asgari Z. Int J Gynaecol Obstet. 2009 Sep 1.
- 85.** Metformin Does Not Improve the Reproductive or Metabolic Profile in Women With Polycystic Ovary Syndrome (PCOS). Aubuchon M, Lieman H, Stein D, Cohen HW, Isaac B, Adel G, Weitzman V, Tetrokalashvili M, Polotsky AJ, Santoro N. Reprod Sci. 2009 Aug 19
- 86.** Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial. Otta CF, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, Wyse EP. Gynecol Endocrinol. 2009 Aug 27:1-6.
- 87.** The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Katsiki N, Georgiadou E, Hatzitolios AI. Drugs. 2009;69(11):1417-31.
- 88.** Insulin-sensitising drugs for polycystic ovary syndrome. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Cochrane Database Syst Rev. 2009 Jul 8; (3):CD003053.

2009 3rd Quarter Literature Review

89. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Billa E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S, Antsaklis A, Adamopoulos DA. Gynecol Endocrinol. 2009 Jun 15:1-8.
90. Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome. Motta AB. Curr Pharm Des. 2009;15(26):3074-7.
91. Metformin inhibits aromatase via an ERK (extracellular signal-regulated kinase) - mediated pathway. Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD. Endocrinology. 2009 Jul 2.

TREATMENT OF PCOS - AROMATASE INHIBITORS

92. Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome. Eckmann KR, Kockler DR. Ann Pharmacother. 2009 Jul; 43(7):1338-46.
93. Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Abu Hashim H, Shokair T, Badawy A. Fertil Steril. 2009 Sep 2.

TREATMENT OF PCOS – IN VITRO FERTILIZATION

94.Should patients diagnosed with polycystic ovary syndrome (PCOS) participate in compensated egg sharing in return for subsidized fertility treatment? **Heng BC.** Hum Reprod Genet Ethics. 2009;15(1):4-6.

95.Infertility, medical advice and treatment with fertility hormones and/or in vitro fertilisation: a population perspective from the Australian Longitudinal Study on Women's Health. **Herbert DL, Lucke JC, Dobson AJ.** Aust N Z J Public Health. 2009 Aug;33(4):358-64.

2009 3rd Quarter Literature Review

ULTRASOUND-IMAGING

96. Three-dimensional ultrasound features of the polycystic ovary in Chinese women. Lam P, Raine-Fenning N, Cheung L, Haines C. Ultrasound Obstet Gynecol. 2009 Jul 30;34(2): 196-200.
97. Endometrial blood flow is impaired in women with polycystic ovarian syndrome who are clinically hyperandrogenic. Lam P, Johnson I, Raine-Fenning N. Ultrasound Obstet Gynecol. 2009 Sep;34(3):326-34.

MISCELLANEOUS

98. A Novel Association Between Polycystic Ovary Syndrome and Helicobacter pylori. Yavasoglu I, Kucuk M, Cildag B, Arslan E, Gok M, Kafkas S. Am J Med Sci. 2009 Jul 8.
99. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber T, Obermayer-Pietsch B. Eur J Endocrinol. 2009 Jul 23.
100. Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome. Mathur R, Ko A, Hwang LJ, Low K, Azziz R, Pimentel M. Dig Dis Sci. 2009 Aug 21.